PREFRENTIAL WARRANTS ALLOTMENT

Warrants ConvertedFund Raising View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.0%Reaction day

₹35.30

prior close

₹33.54

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-4.9% vs market

Pharmaceuticals peers, median of 162sector+0.1%-5.0% vs sector

On the reaction day the stock moved 4.9 pts less than Nifty Microcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.0-0.1-4.9+0.1-5.0

Next day

-9.7-1.5-8.2+0.1-9.8

-14.2-4.5-9.7-1.5-12.8

-9.9-3.9-6.1-1.9-8.0

-9.3-3.6-5.7-1.6-7.7

-11.0-4.0-7.0-1.7-9.3

-13.5-4.9-8.6-2.0-11.4

15d

-17.6-2.7-14.9-0.7-16.8

-9.4-2.5-6.9-1.6-7.8

-4.2+2.7-6.9+3.4-7.6

+13.5+8.4+5.1+5.9+7.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shukra Pharmaceuticals' board approved conversion of 17,35,000 share warrants into equity shares by promoters Dakshesh Shah (5 lakh warrants) and Parshva Texchem India Pvt Ltd (12.35 lakh warrants). The exercise price of Rs. 25.50 per share (being 75% of the warrant price of Rs. 34) brought in Rs. 4.42 crore. Paid-up capital increased from Rs. 43.79 crore to Rs. 43.96 crore. The company also declared a nominal dividend of Re. 0.01 per share for FY26. Financially, standalone revenue grew 74% to Rs. 56.71 crore while net profit more than doubled to Rs. 22.05 crore. A new MedTech segment was launched in October 2025, and the company now has 4 subsidiaries.

Likely market impact

Promoter stake increased through warrant conversion, causing dilution for existing shareholders. Strong profit growth of 130% year-on-year is positive, but remaining 29.08 lakh outstanding warrants pose further dilution risk.